At a glance
- Originator Novo Nordisk
- Class Aminopyridines; Antiglaucomas; Organic sulfur compounds; Small molecules
- Mechanism of Action Somatostatin receptor agonists; Somatostatin receptor subtype 4 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Glaucoma
Most Recent Events
- 27 Jun 2001 No-Development-Reported for Glaucoma in USA (Unknown route)
- 28 Oct 1998 Preclinical development for Glaucoma in USA (Unknown route)
- 01 Oct 1998 New profile